Rx (Prescription Medicine)
USD $ 150.00
Nintib 150mg Capsule 是一种靶向治疗药物，用于治疗某些类型的癌症。其活性成分 Nintedanib 是一种酪氨酸激酶抑制剂。它通过阻断特定酶的活性，从而抑制癌细胞的生长和转移。通过抑制这些通路，Nintedanib 有助于减缓或停止疾病的进展。
Nintib 150mg Capsule 主要用于治疗特发性肺纤维化（IPF），这是一种以肺组织瘢痕形成为特征的慢性且进展性的肺部疾病。它也用于与多柔比星联合使用，用于治疗已转移的非小细胞肺癌（NSCLC）腺样癌，在一线化疗之后。通常剂量为 IPF：150mg 两次/天，NSCLC：150mg 两次/天，与食物同服。但剂量可能根据个体的反应和耐受性由医疗专业人员进行调整。
常见不良反应可能包括腹泻、恶心、呕吐、腹痛、食欲下降以及肝酶升高。严重不良反应可能发生，患者应立即向医生报告任何异常症状。Nintib 150mg Capsule 应储存在室温，避免潮湿和热源。务必严格按照医生的处方服用此药，并避免在治疗期间摄入柚子或柚子汁，因为它们可能影响药物的疗效。
| Molecule | |
|---|---|
| Strength | |
| Pack Quantity | |
| Medicine Form | |
| Medicine Type | |
| Rx Status | |
| Country Of Origin | |
| Packaging Type | |
| Brand Name |
其他品牌的 Nintedanib 150 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
